ReviewNeurogenetics2025
Strabismus and nystagmus in oculocutaneous albinism: clinical perspectives, diagnosis, and role of neurotransmitters.
Review in Neurogenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rare recessive autosomal non-communicable disorder oculocutaneous albinism causes discoloration of the eye, hair, and skin. Oculocutaneous albinism is a hereditary group of disorders with sub-differential characteristics like reduction of pilar, cutaneous, and ocular pigmentation. Clinical characteristics and symptoms include strabismus, iris hypopigmentation, nystagmus, reduced visual acuity, foveal hypoplasia, refractive errors, photophobia, and colour-visual impairment. The associated genetic mutation results in the reduced activity of tyrosine activity required for the metabolism of melanin further. Genes that are majorly involved in different types of oculocutaneous albinism (OCA) are the TYR, MATP, SLC24A5, TYRP1, and SLCA5A2. Also, gene sequences LYST and HPS1 account for Chediak-Higashi syndrome and Hermansky-Pudlak syndrome, respectively, which have clinical symptoms of OCA. The exact gene mutation can be understood by various methods of a diagnostic approach, like denaturing high-performance liquid chromatography and sequential analysis that involves computational techniques. The most prevalent form of albinism, OCA1, is associated with a mutational defect in the TYR gene. Further, neuromodulators like GABA, acetylcholine, and dopamine are responsible for retinal abnormality and dysregulation, exacerbating the oculocutaneous albinism. Understanding all these genetic mutations and neurotransmitter deficiencies will help in generating the targeted gene and other drug delivery systems.
Indexed as
Identifiers
40531243What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.